ClinicalTrials.Veeva

Menu

To Evaluate Safety and Efficacy of EC-18 in COVID-19 Infection to Pneumonia

E

Enzychem Lifesciences

Status and phase

Completed
Phase 2

Conditions

COVID-19

Treatments

Drug: Placebo EC-18
Drug: EC-18

Study type

Interventional

Funder types

Industry

Identifiers

NCT04500132
EC-18-C201

Details and patient eligibility

About

Prevention of COVID-19 infection to severe pneumonea or ARDS

Enrollment

63 patients

Sex

All

Ages

19+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Signed informed consent
  • Male or female age 19 years or older
  • Pathologically confirmed diagnosis of COVID-19 Infection to Pneumonia

Exclusion criteria

  • Pathologically confirmed diagnosis of bacterial pneumonia or viral pneumonia
  • Pregnant or nursing at the time of signing informed consent
  • Known sensitivity to any study medication
  • Unwilling or unable to complete study diary
  • Any other condition or prior therapy that, in the opinion of the Investigator, would make the subject unsuitable for the study or unable to comply with the protocol

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

63 participants in 2 patient groups, including a placebo group

EC-18 Arm
Experimental group
Description:
EC-18 QD
Treatment:
Drug: EC-18
Placebo Arm
Placebo Comparator group
Description:
Placebo EC-18 QD
Treatment:
Drug: Placebo EC-18

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems